In recent days, BeOne Medicines AG gained fresh attention as Wolfe Research initiated coverage with an Outperform rating and the company secured FDA orphan drug designation for its hepatocellular ...

CatalYm has dosed the first patient in its global GDFATHER-HCC-01 study, a phase 2b trial evaluating visugromab in combination with chemoimmunotherapy for people with unresectable or metastatic ...

Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

Orphan Drug Designation is a key incentive established by the EMA to facilitate the development and authorisation of ...

AstraZeneca (AZN) announced on Thursday that a combination regimen containing its antitumor agent, Imfinzi, was successful in a late-stage trial for a subset of patients with hepatocellular carcinoma, ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

AstraZeneca ( (GB:AZN) ) has shared an announcement.

Liver cancer is one of the world's deadliest cancers, and most cases are linked to chronic viral hepatitis. Yet scientists have lacked an animal model that faithfully recapitulates how the disease ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...